US-based small-molecule drug provider Frequency Therapeutics has completed a series A financing round to raise $32m in order to support expanded work to realise the disease-modifying potential of progenitor cell activation (PCA) beyond hearing loss.

Canadian-based medical marijuana provider Emerald Health Therapeutics intends to raise C$17.5m ($13.22m) from an underwritten public offering of units comprising one common share of the company and one-half common share purchase warrant.

The offering includes 9.46 million units priced at C$1.85 ($1.32) a unit.

Underwriters will be granted an option to purchase up to an additional 1.4 million units within 30 days of closure of the offering, in case of over-allotment, if any.

The proceeds will be invested to accelerate the expansion of the company’s facility, as well as for working capital and general corporate purposes.

Holders of the warrants will be entitled to purchase shares of the company at a price of C$2.6 ($1.94) a share for 24 months following the closure of the offering.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"US-based biopharmaceutical company Kadmon Holdings has announced its intention to raise funds through a public offering of equity."

China Resources Development Group will develop and market Immune System Regulation Holding’s (ISR) drug candidates in HIV / AIDS in China, under a partnership agreement signed between the two.

ISR is a research company focused on immunotherapy, while China Resources Development Group is a conglomerate company.

US-based biopharmaceutical company Kadmon Holdings has announced its intention to raise funds through a public offering of equity.

The offering will include issuance of 23.7 million shares of common stock by the company’s selling stockholders.

Endo Designated Activity Company, Endo Finance and Endo Finco, the wholly owned subsidiaries of Irish pharmaceutical company Endo International, intend to raise funds through a private placement of senior secured notes.

The proceeds are intended to repay all outstanding loans of the company and fulfil other obligations under its existing credit facilities.

Chinese-based pharmaceutical company Teyi Pharmaceutical Group intends to raise ¥354m ($51.3m) in a private placement of convertible bonds.